Bitopertin R enantiomer is primarily investigated for its potential therapeutic applications in neurological and psychiatric disorders. It functions as a glycine reuptake inhibitor, which modulates the N-methyl-D-aspartate (NMDA) receptor activity, a key player in synaptic plasticity and cognitive functions. This mechanism makes it a promising candidate for treating conditions such as schizophrenia, particularly in addressing negative symptoms and cognitive impairments that are often resistant to conventional treatments. Additionally, research explores its efficacy in other disorders involving glutamate dysregulation, such as depression and anxiety. Its enantiomeric purity ensures targeted pharmacological activity, potentially reducing off-target effects and improving therapeutic outcomes. Clinical trials are ongoing to evaluate its safety, tolerability, and effectiveness in these applications.